ESC Professional Premium Access

Insights from atrial fibrillation registries and observational studies

Event: ESC Congress 2022
Topic: Prevalence and Incidence of Atrial Fibrillation
Session type: Moderated ePosters
Date: 27 August 2022
Time: 13:15 - 14:00

Congress Session

7 presentations in this session

The first Brazilian cardiovascular registry of atrial fibrillation: The primary results of the RECALL study

Speaker: Doctor R. Lopes (Durham, US)

Lower recurrence rates of atrial fibrillation in early compared to late ablation - a Danish Nationwide study

Speaker: Doctor J. Toennesen (Gentofte, DK)

Prevalence of atrial fibrillation - a comprehensive nationwide analysis in Finland

Speaker: Doctor M. Lehto (Helsinki, FI)

Variations in atrial fibrillation ablation utilization and reimbursement among medicare beneficiaries: an observational study from 2013 to 2019

Speaker: Doctor A. Fath (Phoenix, US)

Results from a nationwide atrial fibrillation screening effort in Belgium

Speaker: Doctor H. Gruwez (Leuven, BE)

Characteristics of incident atrial fibrillation patients - a nationwide register-based study with information from primary-, secondary- and tertiary care

Speaker: Mr E. Kouki (Helsinki, FI)

Impact of sex on the incidence of atrial fibrillation in the community setting: a systematic review and meta-analysis

Speaker: Professor V. Vassiliou (Norwich, GB)

7 speakers from this session

Doctor Renato Lopes

Duke University Medical Center, Durham (United States of America)
20 presentations
0 follower

Doctor Jacob Toennesen

Gentofte University Hospital, Gentofte (Denmark)
0 follower

Doctor Mika Lehto

Helsinki University Hospital, Helsinki (Finland)
0 follower

Doctor Ayman Fath

Creighton University Arizona Health Education Alliance, Phoenix (United States of America)
0 follower

Doctor Henri Gruwez

University Hospitals (UZ) Leuven, Leuven (Belgium)
0 follower

Mr Elis Kouki

University of Helsinki, Helsinki (Finland)
0 follower

Professor Vassilios Vassiliou

University of East Anglia, Norwich (United Kingdom of Great Britain & Northern Ireland)
4 presentations
0 follower

This platform is supported by

logo Novo Nordisk